The Academy for Clinical Debates & Controversies in Medicine Announces:

THE 2nd ASIA PACIFIC CONGRESS ON
CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY

Shangri-La Hotel, Shanghai, China • November 8-11 2007

2nd ANNOUNCEMENT
AND CALL FOR ABSTRACTS

Under the auspice of:
Asia & Oceania Federation of Obstetrics & Gynaecology

www.comtecmed.com/cogi/china

Deadline for abstracts submission: July 31st, 2007
Dear Friends and Colleagues,

Since its inception in 1999, the COGI Congresses have become recognized as outstanding and comprehensive conferences dealing with all the burning issues of our profession with evidence-based discussions.

The COGI Congresses provide an effective forum for discussion and interaction by providing world-renowned experts to impart their experience and expertise in all areas of obstetrics and gynecology: Perinatology family planning, Menopause, Endoscopy, Oncology, Ultrasonography, and Infertility.

It is with great pleasure that we invite you to join us at the 2nd Asian Pacific Congress in Shanghai, China in November 2007. Judging by the positive and encouraging responses received, this meeting will uphold the COGI tradition of being an outstanding scientific and social event.

Shanghai, a city with a pleasant climate, has witnessed rapid development in finance, transport, real estate, telecommunications, tourism, industry, conventions and exhibitions, while maintaining its traditional cultural history.

Therefore we feel it is the appropriate venue for the new and innovative ideas such as those presented at the COGI Congresses.

We invite you to join us at the 2nd Asian Pacific Congress, also called "Hu" or "Shen" in Chinese, which promises to be an outstanding scientific event and an opportunity to visit the vibrant, modern China.

Hoping to see you with us in China.

Prof. JH. Lang
Honorary President

Organizing Committee

Z. Bhutta Z.Y. Cao C. Chen W. Di T.T. Hsieh
Ko-En Huang C. Kamheang Y. Murata W.W. Sumpalco Y.F. Wang
Z. Ben Rafael T. Duan Q. Yu P.C. Wong
Z. Shoham
Local Scientific Committee

G.A. Chen  T. Duan  L.H. Han  R.Z. Li  Z.L. Peng  L.H. Wei  D.Z. Yang
L.N. Cheng  G.S. Fan  K.Q. Hua  Q.D. Lin  J. Qiao  E.L. Xia  Q. Yu
G.S. Fan  Y.J. Feng  Y.L. Hu  S.Q. Lin  K. Shen  L. Xu  W.Y. Zhang

Endorsements
Federation of Asia & Oceania Perinatal Societies (FAOPS)
Asia Pacific Menopause Federation (APMF)
Shanghai Medical Association
Shanghai Society of Obstetrics & Gynaecology
Shanghai 1st Maternity and Infant Hospital
Department of Obstetrics & Gynecology of Peking Union Medical College Hospital
Shanghai Obstetrics and Gynecology Hospital of Fudan University
Indian Society of Perinatology and Reproductive Biology (ISOPARB)
International College of Surgeons

Sponsors

Preliminary Program

PRE-CONGRESS SATELLITE SYMPOSIA
Thursday, November 08, 2007

Pre-congress Satellite Symposia Asia-Pacific Council on Contraception (APCOC)
Sponsored by

INFERTILITY AND ASSISTED REPRODUCTIVE TECHNOLOGIES (ART)

Friday, November 09, 2007
SESSION: INFERTILITY WORK-UP
Capsule: Do we need all the preliminary tests?
- No more need for hysterosalpingogram to diagnose uterine anomalies: We now have 3D ultrasound
- Sophisticated sperm analysis - is it ever required?
- Should we abandon diagnostic laparoscopy before IVF?

SESSION: CONTROVERSIAL ISSUES IN INFERTILITY AND ART TREATMENT
Capsule: Practical issues regarding infertility treatment before and during IVF are not always clear.
Preliminary Program

INFERTILITY AND ASSISTED REPRODUCTIVE TECHNOLOGIES (ART)

- Why did we stop performing ZIFT?
- Cytoplasmatic transfer for egg factor - is this procedure still performed?
- How can embryo transfer (ET) be improved?
- Should we routinely support the luteal phase with aspirin or Estradiol, or both?

SESSION: STEM CELLS AND PGD

Capsule: Stem cells are emerging as a future tool for therapy. What are today's options?
- Stem cell therapeutic potential: Is the future here?
- Human embryonic stem cell lines with genetic disorders: What can be learned?
- The future of PGD

SESSION: OVULATION INDUCTION - AROMATASE INHIBITORS: A NEW PLAYER ON THE BLOCK?

Debate: Aromatase inhibitors show promising results in infertility treatment.

Are we sure of the evidence? Do we know the risks?
- Yes: Aromatase inhibitors are efficient and safe!
- No: Aromatase inhibitors - the risk is too high, the evidence is not there!
- Potential use of aromatase inhibitors in IVF patients.

SESSION: OVARIAN STIMULATION REGIMENS

- Diagnosis and treatment of diminished ovarian reserve in an IVF setting
- Antagonist vs. agonist: What is preferable?
- Avoidance of ovarian hyperstimulation syndrome (OHSS)

SESSION: PREGNANCY LOSS

Capsule: Can we identify the etiology for pregnancy loss? Can we prevent it?
- Can PGD overcome recurrent pregnancy failure?
- Pre-implantation screening – does it increase success rate?
- Immunotherapy - is it of any value?
- Late cerclage - is it effective?

SESSION: HOT CONTROVERSIES – FREE COMMUNICATIONS

SESSION: INNOVATIVE TECHNIQUES IN IVF

Capsule: Should we keep using new techniques that have a marginal degree of success?
- Restoring female reproduction by oocyte freezing – is it cost effective?
- Fertility preservation in cancer patients
- IVM - will it ever replace standard IVF?
- Blastocyst vitrification

SESSION: PCOS

Capsule: The most common endocrinopathy remains an enigma in many aspects
- Resistance to CC in PCOS patients - how to proceed?
- Ovarian drilling or OI for PCOS?
- Minimal monitoring of ovarian stimulation – is it safe?
- Metformin for all patients with PCOS

ENDOSCOPY/MENOPAUSE, FAMILY PLANNING AND ONCOLOGY

- Should tibolone be prescribed in perimenopause to treat androgen deficiency?

LUNCH SESSION: QUALITY OF LIFE BENEFITS IN ORAL CONTRACEPTION

Sponsored by Bayer (South East Asia) Pte Ltd

SESSION: PAIN AND ENDOMETRIOSIS

Capsule: Controlling pelvic pains requires surgical and medical skills
ENDOSCOPY/MENOPAUSE, FAMILY PLANNING AND ONCOLOGY

• Deep endometriosis: how to diagnose, when to treat?
• Surgery Vs. medical therapy in pelvic pain patients: what to prefer first?
• Presacral neurectomy: can it control pelvic pain?
• Endometriomas: Cystectomy or coagulation?

SESSION: LAPAROSCOPY - HYSTERECTOMY AND COMPLICATIONS

Capsule: Laparoscopy is a potent operative tool, but the debate regarding safety and indications is still ongoing
• Should all hysterectomies be performed laparoscopically?
• Laparoscopic access: What about safety?
• Laparoscopic supracervical hysterectomy: Is leaving the cervix a problem?

SESSION: HOT CONTROVERSIES IN GYNECOLOGY

Saturday, November 10, 2007

SESSION: SEXUAL DYSFUNCTION

Capsule: Is there a simple agreed choice for treatment in males or females?
• Treatment of female sexual dysfunction by testosterone
• Psychological aspects of sexual dysfunction in women
• How women are affected by erectile dysfunction in their partner

SESSION: MENOPAUSE MANAGEMENT

Sponsored by Bayer (South East Asia) Pte Ltd

SESSION: HPV VACCINATION

Capsule: The new promising development in the prevention of cervical cancer raises many questions

SESSION: TREATING MENOPAUSAL SYMPTOMS UNDER THE WHI?

Capsule: Does WHI indicate the end of HRT?
• Does the WHI data have any application in current practice?
• WHI: The progestin story
• Androgen therapy in menopause

SESSION: HOT CONTROVERSIES IN GYNECOLOGY - FREE COMMUNICATIONS

Sunday, November 11, 2007

SESSION: GENITAL MALIGNANCIES

Capsule: Are the new aggressive procedures coupled with better survival rates?
• Aggressive cytoreductive surgery should be the first step in the management of ovarian cancer?
• Neo-adjuvant chemotherapy for advanced-stage ovarian cancer and cervical cancer
• Intraperitoneal chemotherapy for ovarian cancer: should it now be the standard of care?
• Low potential malignant tumors of the ovary: to surgically ‘stage or not to stage’?

SESSION: LAPAROSCOPIC ONCOLOGY

Capsule: Laparoscopy is a potent tool in advanced surgery, but the debate regarding safety and indications in patients with gynecological cancer still continues

Debate: Adnexal mass:
First choice should be laparoscopy. Is laparotomy the safest mode?

Debate: Endometrial cancer:
First choice should be laparotomy? Should first choice be laparoscopy?
# Preliminary Program

## FETO-MATERNAL MEDICINE

### Friday, November 09, 2007

**SESSION: MULTIPLE PREGNANCIES**

**Capsule:** Reducing multiple pregnancy rate starts with understanding the risks involved

- Obstetrical and perinatal outcome in multiple gestations after IVF
- Should we always reduce triplets?
- Is there a justification for umbilical cord occlusion in multiple pregnancies?
- What is the best treatment for an acardiac twin?

### SESSION: PREMATURITY

**Capsule:** Prevention of prematurity: is it an elusive goal?

- Acute tocolysis: do we have a choice?
- Tocolysis: is it outdated?
- PROM after 34 weeks: to induce or not to induce?
- Tocolytic Efficacy: What is the best option?

### SESSION: PRENATAL DIAGNOSIS AND TREATMENT

**Capsule:** Do increased diagnostic capabilities create more concern?

- Screening for Down syndrome with nuchal translucency and nasal bone vs. maternal serum markers
- What can biochemical testing add to nuchal translucency?
- Increased nuchal translucency with normal karyotype: Should we ignore it?

### Saturday, November 10, 2007

**SESSION: FETAL GROWTH**

**Capsule:** What are the most appropriate strategies for preventing complications due to growth problems?

- What are the perinatal effects of intrauterine growth retardation (IUGR)?
- How should we screen for fetal growth problems?
- How do we diagnose fetal growth restriction?
- Which investigations are required for decreased fetal movements?
- What are the evidence-based protocols for antenatal surveillance?

**SESSION: PRENATAL SCREENING AND DIAGNOSIS**

**Capsule:** No consensus exists regarding the best method of screening for fetal anomalies

### SESSION: DELIVERY PRACTICE

**Capsule:** Are new practices based on evidence?

**Debate:** Cesarean section on demand

**Pros:**
- The role of vaginal birth after cesarean section (VBAC)
- CS for all breech deliveries?

**Cons:**
- The 2nd Asian Pacific Congress on Controversies in Obstetrics and Gynecology
  Shangri-La Hotel, Shanghai, China, November 8-11, 2007
General Information

LOCATION
Pudong Shangri-La
33 Fu Cheng Lu, Pudong, Shanghai 200120, China
Tel: + 86 21 6882 8888
Fax: + 86 21 6882 9998

<table>
<thead>
<tr>
<th></th>
<th>Until July 1, 2007</th>
<th>From July 1, 2007</th>
<th>On Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants - Physicians and scientists</td>
<td>€410</td>
<td>€460</td>
<td>€510</td>
</tr>
<tr>
<td>Nurses, Students/Trainees*</td>
<td>€320</td>
<td>€360</td>
<td>€390</td>
</tr>
<tr>
<td>Accompanying Persons</td>
<td>€120</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Registration form must be accompanied by a letter from the head of the department, confirming their status

Registration fee includes participation in scientific sessions, congress bag, program and abstract book, all printed material of the congress, invitation to the Welcome Reception, Coffee breaks, lunch on Friday and Saturday.

For more details please check our website at: www.comtecmed.com/cogi/china/

ACCOMMODATIONS
Comtec is the professional congresses organizer of the 2nd Asia-Pacific Congress on Controversies in Obstetrics, Gynecology and Infertility and will be offering special reduced rates for accommodation at the Congress venue.

For special rates please check our website at: www.comtecmed.com/cogi/china/

ABSTRACTS FOR THE CONGRESS
• Participants who wish to give a presentation at the Congress are requested to submit an abstract for review by the Scientific Committee.
• Accepted abstracts will be presented as posters.
• Abstracts will be published in the abstract book only on receipt of registration payment in full.

DEADLINES FOR ABSTRACT SUBMISSION:
July 31, 2007
Mirena® product description: Mirena® is a levonorgestrel-releasing intrauterine system (IUS) with an initial release rate of 20 microgram/24 h. Mirena® is inserted into the uterine cavity by a trained health professional. One administration is effective for five years. Indication: Contraception, idiopathic menorrhagia, protection from endometrial hyperplasia during estrogen replacement therapy. Contraindications: Known or suspected pregnancy, current or recurrent pelvic inflammatory disease, lower genital tract infection, postpartum endometritis, infected abortion during the past three months, cervicitis, cervical dysplasia, uterine or cervical malignancy, progestogen-dependent tumors, undiagnosed abnormal uterine bleeding, congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity, conditions associated with increased susceptibility to infections, acute liver disease or liver tumor, hypersensitivity to constituents of the preparation. Marketing authorization holder: BAYER SCHERING PHARMA AG (local subsidiary). Corporate address: BAYER SCHERING PHARMA AG, D-13342 Berlin, Germany. For full product information see package insert or consult our scientific literature. Approved indications, price and reimbursement may differ between countries; for further information, please contact the local Bayer Schering Pharma office. www.bayerscheringpharma.de www.mirena.com